top of page
Search

MHRA, Trading Standards & Police Investigations into Peptide Injections -Defence Lawyer

Skinny Jab Investigations: Unlicensed weight loss medicines, online sales, beauty clinics and the growing risk of MHRA, police and Trading Standards action.


The market for weight loss injections has changed rapidly. Demand for medicines such as tirzepatide has created a lucrative and increasingly risky grey market, with unlicensed products, imported peptides and so-called “research chemicals” being sold online, through social media, private messaging groups, beauty clinics and informal supply networks.


For individuals and businesses involved in the sale, supply, advertising, importation or administration of these products, the legal risk is significant.


The Medicines and Healthcare products Regulatory Agency is now taking visible enforcement action, often working alongside police forces, Trading Standards and financial investigators. Recent activity has included raids on suspected illicit production facilities, seizure of unlicensed pens, packaging, raw chemical ingredients and suspected criminal cash.


This is no longer simply a regulatory concern. It can become a criminal investigation involving dawn raids, interviews under caution, account freezing orders, restraint orders, confiscation risk and reputational damage.


What can be found below:




The Growth of the Illegal Weight Loss Injection Market


Weight loss injections have become one of the most commercially sensitive areas of medicines enforcement in the UK. Legitimate prescription medicines can only be supplied through lawful clinical and pharmacy channels. However, demand, price pressure and online advertising have created opportunities for unlawful sellers.


Products may be marketed as:


  • “skinny jabs”;

  • GLP-1 or GIP-related peptides;

  • tirzepatide alternatives;

  • retatrutide pens or vials;

  • cagrilintide products;

  • laboratory research chemicals;

  • “not for human consumption” compounds;

  • weight loss kits sold through salons, websites or social media.


In many cases, the presentation of the product, customer base, website wording, payment process, testimonials, dosage information, packaging or communications may suggest that the product is intended for human use, even where the seller has included a disclaimer stating that it is for research purposes only.

That is where criminal exposure can arise.


Retatrutide: Experimental, Unapproved and Not for Human Consumption


Retatrutide is a developing weight loss medicine. It has attracted attention because of its potential effect on weight loss, but it does not currently have regulatory approval for ordinary UK medical use.


Outside properly authorised clinical trials, retatrutide should not be sold to the public for weight loss. It is not an authorised UK medicine for general human use. Products claiming to contain retatrutide may therefore raise immediate concerns under the Human Medicines Regulations 2012.


A seller cannot avoid this risk simply by describing the product as a peptide, research chemical or laboratory compound if the surrounding evidence suggests that it is being sold for use by customers seeking weight loss.


Investigators may look at the whole picture, including:


  • website wording and product descriptions;

  • before-and-after images;

  • customer reviews;

  • social media promotion;

  • WhatsApp, Telegram or email messages;

  • dosage guidance or injection instructions;

  • payment references;

  • packaging and labelling;

  • repeat customer patterns;

  • links to beauty or aesthetics services.


Where the evidence suggests that the product was intended for human use, the “not for human consumption” label may be treated as a front rather than a defence.


Tirzepatide: Prescription-Only Medicine and Criminal Supply Risk


Tirzepatide is different from retatrutide because authorised products containing tirzepatide may be available through a lawful prescription. However, that does not mean anyone can sell it.


Under the Human Medicines Regulations 2012, prescription-only medicines are tightly controlled. Regulation 214 provides that a person may not sell or supply a prescription-only medicine except in accordance with a prescription given by an appropriate practitioner.


That means online sellers, salons, informal suppliers, unauthorised clinics or individuals supplying tirzepatide without lawful prescription and pharmacy controls may face criminal investigation.


The fact that a substance may exist as a legitimate medicine in some circumstances does not make its unauthorised sale lawful.


Cagrilintide and Other Emerging Weight Loss Products


Cagrilintide and other emerging weight loss compounds are also likely to attract enforcement attention where products are being advertised or supplied outside lawful medicines regulation.


The MHRA has warned against buying weight loss medicines without a prescription. That warning is especially important where products are obtained through websites, private sellers, social media adverts, beauty salons or overseas suppliers.


For investigators, the key issue will often be whether the product is being sold, supplied, advertised or administered as a medicine without the required authorisation, prescription controls or lawful supply chain.


The Human Medicines Regulations 2012


Several parts of the Human Medicines Regulations 2012 may be relevant:


  • Regulation 46 - prohibits the sale, supply or offer to sell or supply an unauthorised medicinal product. This is highly relevant where a product is being sold as a medicine, or with medicinal claims, without the necessary UK authorisation.


  • Regulation 214 - controls the sale and supply of prescription-only medicines. This is relevant to drugs such as tirzepatide where lawful supply depends on prescription and regulated pharmacy controls.


  • Regulation 255 - creates criminal offences for breaches of specified requirements under the Regulations. Depending on the facts, offences can expose individuals and businesses to prosecution, financial penalties, imprisonment risk and associated proceeds of crime proceedings.


The legal analysis is fact-sensitive. The wording on a website is important, but it is not the only issue. Investigators will usually examine what the seller actually did, who the customers were, how the product was promoted, whether human use was implied, and whether the business model was designed to evade medicines regulation.


The “Research Chemical” Loophole


One of the most common features of this market is the use of disclaimers.


Websites may state that products are:


  • for laboratory research only;

  • not for human consumption;

  • supplied as peptides only;

  • not medicines;

  • not intended to diagnose, treat or prevent disease.


Those words may help in a genuinely lawful scientific supply context. They will not necessarily protect a seller where the evidence points the other way.


A disclaimer may be undermined by weight loss branding, customer targeting, implied usage, dosage information, injection-related accessories, influencer marketing, private messages, or the absence of any genuine laboratory customer base.


In practice, investigators are likely to ask whether the “research” label reflects reality or whether it is being used to disguise the unlawful supply of medicines to the public.


How Investigations May Begin


Skinny jab investigations may begin in several ways. A complaint from a customer, adverse health incident, suspicious online advert, intelligence from Trading Standards or the National Crime Agency, referral from a payment provider, social media monitoring, border seizure, test purchase or MHRA intelligence report may all trigger enforcement action.


Individuals and businesses may first become aware of an investigation when:


  • premises are searched;

  • stock, phones, computers and packaging are seized;

  • bank accounts are frozen;

  • online platforms or websites are taken down;

  • payment processors suspend funds;

  • Trading Standards request information;

  • MHRA officers make contact;

  • police invite an individual for interview under caution.


The early stage of an investigation is often the most important. What is said, disclosed, conceded or misunderstood at the outset can shape the direction of the entire case.


Dawn Raids, Search Warrants and Seizure of Products


Where investigators suspect unlawful manufacture, supply or distribution, enforcement action may be immediate.


A dawn raid or search warrant can lead to seizure of:


  • weight loss pens;

  • vials and peptides;

  • raw chemical ingredients;

  • packaging and labels;

  • injection equipment;

  • phones, laptops and business records;

  • customer lists;

  • cash;

  • cryptocurrency devices;

  • shipping records;

  • bank and payment platform information.


The seizure of stock can immediately disrupt a business. It can also create wider exposure if investigators believe there is evidence of organised supply, money laundering, unsafe products or deliberate evasion of regulatory controls.


Account Freezing Orders, Restraint Orders and Asset Recovery


Medicines investigations increasingly involve financial investigation.  Where investigators suspect that money in a bank account represents the proceeds of unlawful supply, they may seek an Account Freezing Order under the Proceeds of Crime Act 2002. This can prevent access to business or personal funds at an early stage, often before any criminal charge.


In more serious cases, investigators may consider restraint orders, cash seizure, crypto asset freezing or confiscation proceedings if a conviction is obtained. These steps can have a severe impact on cash flow, business operations, housing transactions and ordinary financial commitments.


The MHRA Criminal Enforcement Unit has financial investigation capability and may work with other enforcement bodies to trace, freeze and recover assets suspected to be linked to medicines crime.



A person suspected of involvement in the unlawful sale or supply of weight loss injections may be arrested or asked to attend a voluntary interview under caution.


This should not be treated as a routine meeting.  The interview may focus on:


  • who sourced the products;

  • whether the products were authorised;

  • whether the seller knew the medicines were unlicensed;

  • whether customers were told the products were for weight loss;

  • who controlled websites, payment accounts or messaging groups;

  • whether the business had medical or pharmacy oversight;

  • what happened to the money received;

  • whether others were involved in importation, manufacture or supply.


A poorly handled interview can create difficulties that are hard to repair. In some cases, pre-interview representations, disclosure requests, evidence review and a carefully considered interview strategy may make a significant difference.


Potential Allegations


Depending on the facts, investigators may consider allegations relating to:


  • sale or supply of unauthorised medicinal products;

  • unlawful sale or supply of prescription-only medicines;

  • misleading advertising or consumer protection breaches;

  • fraud, where products were misrepresented;

  • money laundering, where proceeds are alleged to derive from unlawful supply;

  • conspiracy, where more than one person is alleged to have been involved;

  • offences linked to importation, storage, labelling, packaging or distribution.


The commercial structure may also be examined. A company director, website operator, aesthetics practitioner, fulfilment provider, marketer, importer, payment account holder or investor may all become part of the investigation depending on their role and knowledge.


Why These Cases Are Legally Complex


Skinny jab investigations are rarely straightforward. They sit between medicines regulation, consumer protection, financial crime and asset recovery.


The defence may need to examine:


  • whether the product was a medicinal product in law;

  • whether it was offered or supplied as a medicine;

  • whether the product was unauthorised;

  • whether the seller knew or ought to have known the regulatory position;

  • whether there was genuine scientific or laboratory use;

  • whether the supply chain was lawful;

  • whether customer communications have been interpreted fairly;

  • whether financial restraint or freezing powers are justified;

  • whether the investigation has been conducted lawfully and proportionately.


The evidence is often digital and document-heavy. Websites, deleted adverts, customer messages, payment records, labels, invoices, supplier communications and social media posts can all become central.


How We Can Help


Early strategic advice is critical in investigations involving weight loss injections, unlicensed medicines and suspected unlawful supply.


Through a regulated law firm, we can assist individuals and businesses facing MHRA, Trading Standards, police or financial investigation action. This includes advising on interviews under caution, search warrants, seized material, account freezing orders, restraint orders and wider criminal exposure.


Support may include:


  • urgent advice following a raid, seizure or warrant;

  • preparing for an interview under caution;

  • reviewing disclosure and investigator allegations;

  • advising on the Human Medicines Regulations 2012;

  • analysing whether products were unauthorised or prescription-only medicines;

  • challenging account freezing orders or restraint orders;

  • preparing representations to investigators or prosecutors;

  • managing reputational and commercial risk;

  • coordinating strategy where directors, employees or businesses are all affected.


Sam Healey has extensive experience advising in serious and complex investigations involving financial crime, regulatory enforcement, asset recovery and pre-charge strategy. His work includes cases involving enforcement agencies, Trading Standards, police economic crime teams, HMRC, the NCA and other domestic and cross-border enforcement bodies.


He has been recognised by Chambers & Partners and The Legal 500 for his work in serious criminal and financial crime matters.


Frequently Asked Questions


Is it illegal to sell retatrutide in the UK?


Retatrutide is not approved for general UK medical use. Outside authorised clinical trials, products claiming to contain retatrutide are likely to raise serious legal concerns. Selling it to the public for weight loss may breach medicines legislation, particularly where it is presented, promoted or supplied as a product for human use.


Does a “not for human consumption” label protect me?


Not necessarily. Investigators will look beyond the label. If the surrounding evidence suggests that the product was being sold for weight loss or human use, the disclaimer may carry limited weight.


Is tirzepatide illegal?


Tirzepatide may be lawful when prescribed and supplied through proper regulated channels. The legal risk arises where it is sold or supplied without a valid prescription, outside pharmacy controls, or through unauthorised online or informal networks.


Can Trading Standards investigate skinny jab sales?


Yes. Trading Standards may become involved where there are consumer protection issues, misleading advertising, unsafe goods, local business activity or online sales affecting consumers. They may work alongside the MHRA and police.


Can the MHRA raid premises?


Yes. Where there is suspected medicines crime, enforcement action may include searches, seizure of products and equipment, digital evidence recovery and coordination with police forces.


Can my bank account be frozen?


Yes. If investigators suspect that money in an account represents proceeds of unlawful medicine supply, an Account Freezing Order may be sought under POCA. This can happen before any charge has been brought.


Should I attend an interview under caution without legal advice?


No. An interview under caution is a formal criminal investigation step. Legal advice should be obtained before answering questions, providing explanations or handing over material.


Can a business be investigated as well as individuals?


Yes. Directors, employees, website operators, companies, payment account holders and connected individuals may all be investigated depending on the evidence.


Speak in Confidence


If you have been contacted by the MHRA, Trading Standards, the police or another enforcement body about the sale, supply, importation or advertising of weight loss injections, early advice is essential.


For a confidential discussion:


Call: 0330 133 2230


Where legal advice or representation is required, this is provided through a regulated solicitors’ practice.


This article is for general information only and does not constitute legal advice. Every case depends on its own facts. SPH Legal operates as a specialist legal consultancy. Where regulated legal services are required, clients are represented by Sam Healey through a regulated law firm. This article is for general information only, does not constitute legal advice, and does not suggest that similar outcomes will be achieved in other matters.

 
 
bottom of page